These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1228412)

  • 1. Combination chemotherapy based on a model of cell recruitment by partial synchronization.
    Pouillart P; Weiner R; Schwarzenberg L; Misset JL; Oldham R; Amiel JL; Mathé G
    Med Pediatr Oncol; 1975; 1(2):123-34. PubMed ID: 1228412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recruitment-chemoradiotherapy with VM 26 (epipodophyllotoxin) for induction treatment of malignant brain tumours.
    Yamamoto H; Shitara N; Takakura K; Sano K
    Acta Neurochir Suppl (Wien); 1979; 28(2):616-8. PubMed ID: 290264
    [No Abstract]   [Full Text] [Related]  

  • 3. Combination chemotherapy with VM 26 and CCNU in primary malignant brain tumors.
    Seiler RW; Vassella F; Markwalder H
    Surg Neurol; 1979 Mar; 11(3):237-42. PubMed ID: 473022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of small cell bronchogenic carcinoma with VM-26.
    Woods RL; Fox RM; Tattersall MH
    Cancer Treat Rep; 1979; 63(11-12):2011-3. PubMed ID: 230897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Trial treatment of glioblastomas in adults and cerebral metastais by adriamycin, VM 26 and CCNU combination. Result of a type II trial].
    Pouillart P; Mathé G; Poisson M; Buge A; Huguenin P; Gautier H; Morin P; Thy HT; Lheritier J; Parrot R
    Nouv Presse Med; 1976 Jun; 5(25):1571-6. PubMed ID: 778798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose teniposide for refractory malignancies: a phase I study.
    de Vries EG; Mulder NH; Postmus PE; Vriesendorp R; Willemse PH; Sleijfer DT
    Cancer Treat Rep; 1986 May; 70(5):595-8. PubMed ID: 3708608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teniposide (VM-26), an overlooked highly active agent in small-cell lung cancer. Results of a phase II trial in untreated patients.
    Bork E; Hansen M; Dombernowsky P; Hansen SW; Pedersen AG; Hansen HH
    J Clin Oncol; 1986 Apr; 4(4):524-7. PubMed ID: 3007684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of teniposide (VM-26) in multiple myeloma.
    Tirelli U; Carbone A; Zagonei V; Brema F; Veronesi A; Grigoletto E; Volpe R
    Am J Clin Oncol; 1985 Aug; 8(4):329-31. PubMed ID: 3909805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II evaluation of teniposide (VM-26) in metastatic breast carcinoma. A Southeastern Cancer Study Group trial.
    Cox EB; Vogel CL; Carpenter JT; Raney M
    Invest New Drugs; 1988 Apr; 6(1):37-9. PubMed ID: 3410666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of VM-26 in patients with metastatic malignant melanoma.
    Bellet RE; Catalno RB; Mastrangelo MJ; Berd D; Koons LS
    Cancer Treat Rep; 1978 Mar; 62(3):445-7. PubMed ID: 348313
    [No Abstract]   [Full Text] [Related]  

  • 11. Preliminary evaluation of VM-26: a new epipodophyllotoxin derivative, in the treatment of urogenital tumours.
    Pavone-Macaluso M; Caramia G; Rizzo FP; Messana V
    Eur Urol; 1975; 1(1):53-6. PubMed ID: 786645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Adriamycin, VM 26, cyclophosphamide and prednisone (AVmCP) combination in the therapy of disseminated lymphoreticulosarcoma (Stages or topographical forms III and IV].
    Misset JL; Pouillart P; Amiel JL; Schwarzenberg L; Hayat M; de Vassal F; Musset M; Belpomme D; Jasmin C; Albahary C; Depierre R; Mathé G
    Nouv Presse Med; 1975 Dec; 4(44):3117-20. PubMed ID: 768904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ["Cellular synchronization" method in treatment of infantile tumors].
    Hurtado T; Fernández P; Muñoz Villa A; González MC; García Miguel P
    An Esp Pediatr; 1976 Dec; 9(9):42-8. PubMed ID: 797280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined VM-26 and cytosine arabinoside in treatment of refractory childhood lymphocytic leukemia.
    Rivera G; Aur RJ; Dahl GV; Pratt CB; Wood A; Avery TL
    Cancer; 1980 Mar; 45(6):1284-8. PubMed ID: 7357520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-drug chemotherapy of bladder cancer with adriamycin, VM-26 or bleomycin. A phase II multicentric, co-operative study.
    Eur Urol; 1976; 2(3):138-41. PubMed ID: 70352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VM-26 and cytosine arabinoside combination chemotherapy for initial induction failures in childhood lymphocytic leukemia.
    Rivera G; Dahl GV; Bowman WP; Avery TL; Wood A; Aur RJ
    Cancer; 1980 Oct; 46(8):1727-30. PubMed ID: 6932995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of teniposide (VM 26) in advanced non-Hodgkin's lymphoma, with emphasis on the treatment of elderly patients.
    Tirelli U; Carbone A; Crivellari D; Volpe R; Franchin G; Veronesi A; Galligioni E; Trovò M; Tumolo S; Grigoletto E
    Cancer; 1984 Aug; 54(3):393-6. PubMed ID: 6375853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of VM-26 in adult malignancies.
    Spremulli E; Schulz JJ; Speckhart VJ; Wampler GL
    Cancer Treat Rep; 1980 Jan; 64(1):147-9. PubMed ID: 7379049
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of VP-16 and the combination of adriamycin and vincristine in advanced breast cancer.
    Eagan RT; Ahmann DL; Bisel HF
    Oncology; 1976; 33(3):146-8. PubMed ID: 1012648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VM-26 as a second drug in the treatment of brain gliomas.
    Kessinger A; Lemon HM; Foley JF
    Cancer Treat Rep; 1979 Mar; 63(3):511-2. PubMed ID: 427830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.